Nexstim Oyj
OMXH:NXTMH
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.19
6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Nexstim Oyj
Free Cash Flow
Nexstim Oyj
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
Nexstim Oyj
OMXH:NXTMH
|
Free Cash Flow
-€1.8m
|
CAGR 3-Years
21%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
R
|
Revenio Group Oyj
OMXH:REG1V
|
Free Cash Flow
€15.2m
|
CAGR 3-Years
0%
|
CAGR 5-Years
15%
|
CAGR 10-Years
14%
|
|
|
M
|
Modulight Oyj
OMXH:MODU
|
Free Cash Flow
-€23m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bioretec Oy
OMXH:BRETEC
|
Free Cash Flow
-€3.6m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
O
|
Optomed Oyj
OMXH:OPTOMED
|
Free Cash Flow
-€3m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
B
|
Biohit Oyj
OMXH:BIOBV
|
Free Cash Flow
-€546k
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
Nexstim Oyj
Glance View
Nexstim Oyj engages in the provision of medical technology products. The company is headquartered in Helsinki, Etela-Suomen and currently employs 37 full-time employees. The company went IPO on 2014-11-14. The company is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company’s systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.
See Also
What is Nexstim Oyj's Free Cash Flow?
Free Cash Flow
-1.8m
EUR
Based on the financial report for Jun 30, 2024, Nexstim Oyj's Free Cash Flow amounts to -1.8m EUR.
What is Nexstim Oyj's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
25%
Over the last year, the Free Cash Flow growth was 59%. The average annual Free Cash Flow growth rates for Nexstim Oyj have been 21% over the past three years , 25% over the past five years .
You don't have any saved screeners yet
